Alzamend Neuro, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326
Mailing Address 480 PEACHTREE ROAD NE, SECOND FLOOR, ATLANTA, GA, 30326
Phone 844-722-6333
Fiscal Year End 0430
EIN 811822909
Financial Overview
FY2025
-$4.51M
Net Income
$4.60M
Total Assets
$3.97M
Stockholders' Equity
$376K
Cash & Equivalents
$-132.33
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 10-Q Quarterly financial report | March 11, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 424B5 Prospectus supplement | March 6, 2026 | View on SEC |
| DEF 14A Definitive proxy statement | February 26, 2026 | View on SEC |
| 4 Insider stock transaction report | December 30, 2025 | View on SEC |
| 4 Insider stock transaction report | December 23, 2025 | View on SEC |
| 10-Q Quarterly financial report | December 9, 2025 | View on SEC |
| 8-K Current report of material events | November 18, 2025 | View on SEC |
| 4 Insider stock transaction report | October 24, 2025 | View on SEC |
Material Events
8-K Financial Distress March 20, 2026
High Impact
- Alzamend Neuro, Inc. received a Nasdaq delisting warning due to failing to meet a key financial rule.
- The company's stockholders' equity fell below the Nasdaq minimum requirement of $2.5 million, reporting approximately $2.2 million.
Insider Trading
SELL 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.